Ventyx Biosciences, Inc.(VTYX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VTYX Ventyx Biosciences, Inc.

Trading 11-29 12:18:15 EST

2.65

+0.00

-0.19%

High2.69	Low2.53	Vol498.40K
Open2.65	D1 Closing2.65	Amplitude6.04%
Mkt Cap187.03M	Tradable Cap131.29M	Total Shares70.71M
T/O1.30M	T/O Rate1.00%	Tradable Shares49.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VTYX","market":"US","secType":"STK","nameCN":"Ventyx Biosciences, Inc.","latestPrice":2.645,"timestamp":1732900692244,"preClose":2.65,"halted":0,"volume":498403,"delay":0,"floatShares":49638838,"shares":70710667,"eps":-2.327124,"marketStatus":"Trading","change":-0.005,"latestTime":"11-29 12:18:15 EST","open":2.65,"high":2.69,"low":2.53,"amount":1298579.2478011998,"amplitude":0.060377,"askPrice":2.65,"askSize":1242,"bidPrice":2.64,"bidSize":811,"shortable":3,"etf":0,"ttmEps":-2.327124,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732903200000},"marketStatusCode":2,"adr":0,"listingDate":1634788800000,"exchange":"NASDAQ","adjPreClose":2.65,"preHourTrading":{"tag":"盘前","latestPrice":2.65,"preClose":2.65,"latestTime":"09:29 EST","volume":3904,"amount":10149.2975104,"timestamp":1732890599917},"postHourTrading":{"tag":"盘后","latestPrice":2.6754,"preClose":2.65,"latestTime":"19:53 EST","volume":19573,"amount":51750.3403,"timestamp":1732755190291},"volumeRatio":0.36521,"impliedVol":0.5199,"impliedVolPercentile":0.1905},"requestUrl":"/m/hq/s/VTYX/wiki","defaultTab":"wiki","newsList":[{"id":"2486836228","title":"Neurogene and Ventyx Biosciences rises after insider buying by executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2486836228","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486836228?lang=en_us&edition=fundamental","pubTime":"2024-11-27 01:15","pubTimestamp":1732641322,"startTime":"0","endTime":"0","summary":"cemagraphics/iStock via Getty Images  Shares of Neurogene (NASDAQ:NGNE) and Ventyx Biosciences (NASDAQ:VTYX) rose after both reported executive insider buys in recent SEC Filings. According to the fil","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1425905549/image_1425905549.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1425905549/image_1425905549.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4336288-neurogene-and-ventyx-biosciences-rises-after-insider-buying-by-executives","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["VTYX","BK4139","NGNE","BK4007"],"gpt_icon":0},{"id":"2484638205","title":"Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2484638205","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484638205?lang=en_us&edition=fundamental","pubTime":"2024-11-17 21:07","pubTimestamp":1731848855,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Ventyx Biosciences' stock price is sensitive to their trading actions. A total of 9 investors have a majority stake in the company with 53% ownership. Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business. A look at the shareholders of Ventyx Biosciences, Inc.  can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 59% ownership. In other words, the group stands to gain the most  from their investment into the company.NasdaqGS:VTYX Earnings and Revenue Growth November 17th 2024. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 16% of Ventyx Biosciences shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation  in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ventyx-biosciences-inc-nasdaq-vtyx-130735378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210149790.SGD","PSQ","LU2210150020.SGD","LU2095319765.USD","BK4007","BK4112","IE00BGHQF748.EUR","TQQQ","NDAQ","IE00B3QW5Z07.USD","SQQQ","QID","BK4588","VTYX","NQmain","MNQmain",".IXIC","IE00BKPKM429.USD","BK4585","QLD","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2482706706","title":"Ventyx Biosciences to Participate in Three Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2482706706","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482706706?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:30","pubTimestamp":1731414600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 12, 2024  -- Ventyx Biosciences, Inc.  , a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Jc2yXxL2ot4T9jD4KxC8DA--~B/aD0xMTM0O3c9NDAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/12b40026a3fa9d74aa047df3c485d3a1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Jc2yXxL2ot4T9jD4KxC8DA--~B/aD0xMTM0O3c9NDAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/12b40026a3fa9d74aa047df3c485d3a1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ventyx-biosciences-participate-three-upcoming-123000699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VTYX"],"gpt_icon":0},{"id":"2482181717","title":"Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2482181717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482181717?lang=en_us&edition=fundamental","pubTime":"2024-11-12 12:01","pubTimestamp":1731384087,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences, Inc. ( ($VTYX) ) has released its Q3 earnings. Here is a breakdown of the information Ventyx Biosciences, Inc. presented to its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ventyx-biosciences-reports-q3-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ventyx-biosciences-reports-q3-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","PRGS","VTYX","LU2065732104.USD","BK4007"],"gpt_icon":0},{"id":"2482759373","title":"Ventyx Biosciences Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482759373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482759373?lang=en_us&edition=fundamental","pubTime":"2024-11-12 02:30","pubTimestamp":1731349800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VTYX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2024 13:30 ET (18:30 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2481105879","title":"Ventyx Biosciences (VTYX) Receives a Buy from LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2481105879","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481105879?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:46","pubTimestamp":1731073587,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report). The company’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ventyx-biosciences-vtyx-receives-a-buy-from-lifesci-capital-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ventyx-biosciences-vtyx-receives-a-buy-from-lifesci-capital-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VTYX"],"gpt_icon":0},{"id":"2481912177","title":"Ventyx Biosciences : Oppenheimer Cuts Target Price to $9 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2481912177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481912177?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:08","pubTimestamp":1731071336,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nAZN2LDYF3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2481194000","title":"Ventyx Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481194000","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481194000?lang=en_us&edition=fundamental","pubTime":"2024-11-08 12:20","pubTimestamp":1731039649,"startTime":"0","endTime":"0","summary":"* Ventyx Biosciences Inc    reported a quarterly adjusted loss of 50 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -92 ce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2481682331","title":"Ventyx Biosciences Q3 EPS $(0.50) Beats $(0.53) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481682331","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481682331?lang=en_us&edition=fundamental","pubTime":"2024-11-08 06:14","pubTimestamp":1731017686,"startTime":"0","endTime":"0","summary":"Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.53) by 5.66 percent. This is a 45.65 percent increase over losses of $(0.92) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41827957/ventyx-biosciences-q3-eps-0-50-beats-0-53-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ventyx Biosciences Q3 EPS $(0.50) Beats $(0.53) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2481151066","title":"BRIEF-Ventyx Biosciences Q3 Net Income USD -35.249 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481151066","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481151066?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013553,"startTime":"0","endTime":"0","summary":"Nov 07 (Reuters) - Ventyx Biosciences Q3 operating expenses USD 38.552 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USD","VTYX","BK4007"],"gpt_icon":0},{"id":"2481689391","title":"Ventyx Biosciences Inc: Cash Balance of $274.8M as of September 30, 2024 Expected to Fund Operations Into at Least H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2481689391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481689391?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA8XBKM6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2481922311","title":"Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2481922311","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481922311?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013500,"startTime":"0","endTime":"0","summary":"Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025. Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025. Cash balance of $274.8M as of September 30, 2024 expected to fund operations into at least H2 2026. “Thanks to the continued execution of our team, we are on track to initiate a Phase 2 trial of VTX2735 in recurrent pericarditis and a Phase 2 obesity and cardiometabolic trial of VTX3232 by the end of this year, in addition to advancing enrollment in the ongoing Phase 2a trial of VTX3232 in patients with early Parkinson’s disease,” said Raju Mohan, PhD, President and Chief Executive Officer. “With our potential best-in-class NLRP3 inhibitors, we believe we are well positioned to unlock the vast therapeutic potential of the inflammasome pathway.”VTX2735 : We expect to initiate a Phase 2 trial of VTX2735 in participa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Jc2yXxL2ot4T9jD4KxC8DA--~B/aD0xMTM0O3c9NDAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/12b40026a3fa9d74aa047df3c485d3a1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Jc2yXxL2ot4T9jD4KxC8DA--~B/aD0xMTM0O3c9NDAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/12b40026a3fa9d74aa047df3c485d3a1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ventyx-biosciences-reports-third-quarter-210500318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4097","LU2065732104.USD","CAPS","PRGS","CSF","VTYX","BK4139"],"gpt_icon":0},{"id":"2481539186","title":"Ventyx Biosciences: Ready To Escape \"The Crash Cycle\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2481539186","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481539186?lang=en_us&edition=fundamental","pubTime":"2024-11-04 23:32","pubTimestamp":1730734370,"startTime":"0","endTime":"0","summary":"And what happened to Ventyx to make i","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1812244974/image_1812244974.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1812244974/image_1812244974.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4732719-ventyx-biosciences-ready-to-escape-the-crash-cycle","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","VTYX"],"gpt_icon":0},{"id":"2480818291","title":"Ventyx Biosciences Inc    expected to post a loss of 52 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480818291","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480818291?lang=en_us&edition=fundamental","pubTime":"2024-11-02 12:05","pubTimestamp":1730520350,"startTime":"0","endTime":"0","summary":"* Ventyx Biosciences Inc     is expected to show no change in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2024   *    * LSEG's mean analyst ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ventyx Biosciences Inc    expected to post a loss of 52 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2479135476","title":"These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2479135476","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479135476?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:01","pubTimestamp":1730196060,"startTime":"0","endTime":"0","summary":"In his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line offers valuable wisdom for investors: no matter the strategy, success in the stock market ultimately depends on how well you navigate the balance between risk and reward.Few corners of the stock market present a greater potential return for the risk than penny stocks, which trade at $5 or less. These ultra-low-priced equities offer an attractive entry point for investors looking to seize high-risk, high-reward opportunities.The low entry cost of penny stocks offers the potential for substantial gains, as even a small increase in share price can lead to impressive percentage returns. It’s not uncommon for penny stocks to have upside potentials of 300%, 400%, or more. However, the other side of the coin is just as important – with high reward comes heightened risk.Looking beyond the current trial, Regulus states that it remains on schedule to meet with the FDA before t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SY13O2aLL5VL4q9G.qWo0A--~B/aD01NDU7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/b6483c0bf949dc997fe1799dff38f019","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SY13O2aLL5VL4q9G.qWo0A--~B/aD01NDU7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/b6483c0bf949dc997fe1799dff38f019"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/2-strong-buy-penny-stocks-100100073.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/2-strong-buy-penny-stocks-100100073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VTYX","RGLS","BK4007"],"gpt_icon":0},{"id":"2475825651","title":"Ventyx Biosciences Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2475825651","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475825651?lang=en_us&edition=fundamental","pubTime":"2024-10-16 01:37","pubTimestamp":1729013820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VTYX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 15, 2024 13:37 ET (17:37 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2475631901","title":"Ventyx Biosciences’ Tamuzimod: Promising Data but Insufficient for Upgrade Beyond Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2475631901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475631901?lang=en_us&edition=fundamental","pubTime":"2024-10-15 23:45","pubTimestamp":1729007109,"startTime":"0","endTime":"0","summary":"Analyst Emily Bodnar from H.C. Wainwright maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) and keeping the price target at $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ventyx-biosciences-tamuzimod-promising-data-but-insufficient-for-upgrade-beyond-hold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ventyx-biosciences-tamuzimod-promising-data-but-insufficient-for-upgrade-beyond-hold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VTYX"],"gpt_icon":0},{"id":"2475750896","title":"Ventyx Biosciences Presents New 52-Week Results From the Phase 2 Trial of Vtx002 (Tamuzimod) in Ulcerative Colitis at Ueg Week 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475750896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475750896?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:00","pubTimestamp":1728993601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nTUA8BCMP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2475503811","title":"Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475503811","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475503811?lang=en_us&edition=fundamental","pubTime":"2024-10-15 20:00","pubTimestamp":1728993600,"startTime":"0","endTime":"0","summary":"Late-breaking abstract highlights high rates of clinical and endoscopic remission among LTE completers at Week 52SAN DIEGO, Oct.  15, 2024  (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/15/2963134/0/en/Ventyx-Biosciences-Presents-New-52-Week-Results-from-the-Phase-2-Trial-of-VTX002-Tamuzimod-in-Ulcerative-Colitis-at-UEG-Week-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2470411938","title":"VTYX Stock Rises on Strategic Equity Investment Deal With SNY","url":"https://stock-news.laohu8.com/highlight/detail?id=2470411938","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470411938?lang=en_us&edition=fundamental","pubTime":"2024-09-24 22:24","pubTimestamp":1727187840,"startTime":"0","endTime":"0","summary":"Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi SNY. Per the terms of the deal, Sanofi will buy 70,601 of Ventyx’s Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock.The proceeds from this investment are anticipated to enhance Ventyx’s cash reserves. With the addition of these funds, the combined total of current cash, cash equivalents and marketable securities is expected to support the company's planned operations until at least the second half of 2026.VTYX Grants SNY Exclusive Rights to Investigational Drug. Ventyx believes that this strategic deal with Sanofi underscores the potential of VTX3232 to offer a disease-modifying treatment for CNS indications with significant unmet medical needs. The company will also be able to utilize Sanofi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OKs2Umbh_jq1JHRq6tWCew--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c1d0d60d32130a1e1beb497a426ea24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OKs2Umbh_jq1JHRq6tWCew--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c1d0d60d32130a1e1beb497a426ea24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vtyx-stock-rises-strategic-equity-142400808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1057294990.SGD","NVO","IE00BFXG1179.USD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU0256863902.USD","BK4588","LU0820561818.USD","CNS","LU0238689110.USD","LU1069344957.HKD","BK4532","LLY","LU1064131342.USD","LU0289739699.SGD","RA","LU1093756168.USD","LU0385154629.USD","LU0466842654.USD","LU0640476718.USD","EQR","LU1023059063.AUD","LU0320765059.SGD","IE00B4R5TH58.HKD","LU0097036916.USD","BK4534","IE0009355771.USD","LU0820561909.HKD","SNY","LU0823416689.USD","LU0006306889.USD","LU0106261372.USD","IE00BK4W5M84.HKD","LU0198837287.USD","LU0417517546.SGD","LU1267930730.SGD","IE00BK4W5L77.USD","IE00BKVL7J92.USD","LU0094547139.USD","LU0471298777.SGD","LU0689472784.USD","BK4581","LU0672654240.SGD","BK4215","LU0154236417.USD","IE00BZ1G4Q59.USD","IE00B2B36J28.USD","VTYX","BK4533","LU0882574139.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://ir.ventyxbio.com","stockEarnings":[{"period":"1week","weight":0.5407},{"period":"1month","weight":0.1472},{"period":"3month","weight":0.2045},{"period":"6month","weight":-0.4456},{"period":"1year","weight":0.1522},{"period":"ytd","weight":0.0729}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.031},{"period":"3month","weight":0.0725},{"period":"6month","weight":0.1355},{"period":"1year","weight":0.3163},{"period":"ytd","weight":0.2599}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.01538},{"month":2,"riseRate":0.666667,"avgChangeRate":0.701385},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.095926},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.042289},{"month":5,"riseRate":0.666667,"avgChangeRate":0.133308},{"month":6,"riseRate":0,"avgChangeRate":-0.288909},{"month":7,"riseRate":1,"avgChangeRate":0.12313},{"month":8,"riseRate":0.333333,"avgChangeRate":0.07183},{"month":9,"riseRate":0.666667,"avgChangeRate":0.241856},{"month":10,"riseRate":0,"avgChangeRate":-0.222243},{"month":11,"riseRate":0.25,"avgChangeRate":-0.190186},{"month":12,"riseRate":1,"avgChangeRate":0.095095}],"exchange":"NASDAQ","name":"Ventyx Biosciences, Inc.","nameEN":"Ventyx Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ventyx Biosciences, Inc.(VTYX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ventyx Biosciences, Inc.(VTYX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ventyx Biosciences, Inc.,VTYX,Ventyx Biosciences, Inc.股票,Ventyx Biosciences, Inc.股票老虎,Ventyx Biosciences, Inc.股票老虎国际,Ventyx Biosciences, Inc.行情,Ventyx Biosciences, Inc.股票行情,Ventyx Biosciences, Inc.股价,Ventyx Biosciences, Inc.股市,Ventyx Biosciences, Inc.股票价格,Ventyx Biosciences, Inc.股票交易,Ventyx Biosciences, Inc.股票购买,Ventyx Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ventyx Biosciences, Inc.(VTYX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ventyx Biosciences, Inc.(VTYX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction